Marina Nechaeva

Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial

Ahmet Sezer, Mahmut Gümüş, Igor Bondarenko et al. · The Lancet · 2021 · 799 citations

Medicine, Oncology, Pharmacology +13

Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial

Cathy Eng, Tae Won Kim, Johanna C. Bendell et al. · The Lancet Oncology · 2019 · 562 citations · Full text

Medicine, Oncology, Pharmacology +11

Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial

Miranda Gogishvili, Tamar Melkadze, Tamta Makharadze et al. · Nature Medicine · 2022 · 301 citations · Full text

Medicine, Oncology, Pharmacology +15

Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100

Markus Moehler, Mikhail Dvorkin, Narikazu Boku et al. · Journal of Clinical Oncology · 2020 · 223 citations · Full text

Medicine, Oncology, Pharmacology +15

Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial

Fred Saad, Egils Vjaters, Neal D. Shore et al. · Journal of Clinical Oncology · 2024 · 141 citations · Full text

Medicine, Oncology, Pharmacotherapy +17